Global Mycoplasma Testing Market Strategic Research Report

Scope of the Report

The global Mycoplasma Testing market size is predicted to grow from US$ 1,132 million in 2025 to US$ 2,601 million in 2032; it is expected to grow at a CAGR of 11.7% from 2026 to 2032.

The gross profit margin of major companies was approximately 45%–68%.

Mycoplasma Testing detects contamination or infection caused by Mycoplasma species using PCR, culture, enzymatic, immunological, or staining methods. It is primarily applied to biopharmaceutical production, cell cultures, vaccines, gene and cell therapies, research samples, and selected clinical specimens. The scope excludes general bacterial testing, endotoxin testing, sterility testing unrelated to Mycoplasma, and contamination-removal services.

The industrial chain includes upstream primers, probes, enzymes, culture media, antibodies, controls, extraction reagents, and analytical instruments. Midstream covers kit manufacturing, sample preparation, amplification, culture, result analysis, quality control, and laboratory services. Downstream users include pharmaceutical companies, biotechnology companies, cell-therapy developers, contract laboratories, research institutions, and hospitals.

Mycoplasma Testing includes products and services used to detect mycoplasma contamination or infection through culture, biochemical analysis, nucleic acid amplification, immunoassays, and other analytical methods. It is widely used in biopharmaceutical manufacturing, cell and gene therapy, vaccine production, cell culture laboratories, clinical diagnosis, and research institutions. In pharmaceutical production, testing helps prevent contaminated cell substrates, raw materials, and biological products from entering downstream processes or being released to market. The industry is moving from traditional culture methods toward rapid PCR, digital PCR, automated sample preparation, high-throughput testing, and validated point-of-use solutions. Growth is driven by expanding biologics and vaccine production, increasing cell and gene therapy pipelines, stricter contamination-control regulations, and greater outsourcing to specialized testing laboratories. Rapid methods are gaining adoption because they shorten testing cycles and accelerate batch release. However, method validation, false-positive risks, matrix interference, laboratory quality requirements, and the relatively high cost of rapid-testing systems remain important constraints.

This report presents a comprehensive overview of the global Mycoplasma Testing market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Nucleic Acid Amplification Testing
• Culture-based Testing
• Immunological and Biochemical Testing

Segment by Sample Type

• Clinical Specimen Testing
• Cell Culture Sample Testing
• Biopharmaceutical Process Sample Testing

Segment by Turnaround Time

• Rapid Testing（≤4 Hours）
• Standard Testing（＞4–48 Hours）
• Extended Testing（＞48 Hours）

Segment by players, this report covers

• Thermo Fisher Scientific Inc.
• Lonza Group AG
• Merck KGaA
• Sartorius AG
• Hologic, Inc.
• Roche Diagnostics
• QIAGEN N.V.
• ATCC
• Promega Corporation
• InvivoGen SAS
• Minerva Biolabs GmbH
• PromoCell GmbH
• Takara Bio Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Shimadzu Diagnostics Corporation
• Seegene Inc.
• Bioneer Corporation
• SolGent Co., Ltd.
• Sansure Biotech Inc.
• Daan Gene Co., Ltd.
• Shanghai ZJ Bio-Tech Co., Ltd.
• Jiangsu Bioperfectus Technologies Co., Ltd.
• Vazyme Biotech Co., Ltd.
• Yeasen Biotechnology (Shanghai) Co., Ltd.
• Beyotime Biotechnology Co., Ltd.
• Shanghai Life-iLab Biotech Co., Ltd.
• Tiangen Biotech (Beijing) Co., Ltd.
• Guangzhou Wondfo Biotech Co., Ltd.
• Guangdong Hybribio Biotech Co., Ltd.

Segment by Application

• Clinical Infection Diagnosis
• Cell Culture Contamination Monitoring
• Biopharmaceutical Quality Control
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Mycoplasma Testing market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Clinical Infection Diagnosis, Cell Culture Contamination Monitoring, Biopharmaceutical Quality Control evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact